Directors show an appetite for Sinclair Pharma shares
Jean-Charles Tschudin, a non-exec director of Sinclair Pharma, acquired 250k shares in the company at 35p per share last week after the company released a strong trading update and announced a distribution and strategic marketing deal in the US. Mr. Tschudin is the third director to purchase shares in the company and now has an interest of 3,250,117 shares or 0.65% of Sinclair Pharma's issued share capital. 

RNS Number : 9402Y

Sinclair Pharma PLC

23 May 2016

Sinclair Pharma plc

Director dealings

23 May 2016,Sinclair Pharma plc (SPH.L) ("Sinclair" or the "Company") the international aesthetics company, was advised on 20 May, that on that day Jean-Charles Tschudin Non-Executive Director, acquired 250,000 ordinary shares of 1p each ("Ordinary Shares") in the Company at 35.0p per Ordinary Share.

Following these purchases, Mr Tschudin is interested in 3,250,117 Ordinary Shares, 0.65% of the issued share capital of the Company.

For further information please contact:

Sinclair Pharma plc Tel: +44 (0) 20 7467 6920

Chris Spooner

Alan Olby

Andy Crane

Peel Hunt LLP Tel: +44 (0) 20 7418 8900

James Steel

Oliver Jackson

Notes to Editors:

About Sinclair Pharma plc

Sinclair Pharma plc is an international c

ompany operating in the fast growth, high gross margin, global aesthetics market.

Sinclair has built a strong portfolio of differentiated, complementary aesthetics technologies, which are experiencing significant growth, targeting unmet clinical needs for effective, high quality, longer duration, natural looking and minimally-invasive treatments. The Company is planning entry to multiple new geographic markets and line extension launches over the next few years.

Sinclair has an established sales and marketing presence in the leading EU markets and Brazil, and a network of international distributors.

For more information, please visitwww.sinclairpharma.com